BAY43-9006 Phase II Study for Renal Cell Carcinoma

NCT00661375 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

131

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Nexavar (Sorafenib, BAY43-9006)

Sponsor

Bayer